文献速递妇科

图像引导近距离放疗在宫颈癌治疗中带来更好临床结局的希望:它真的做到了吗?印度现状

The promise of image-guided brachytherapy of better clinical outcomes in treatment of cervical cancer: Does it deliver? An Indian scenario.
PubMed 文献 · Gynecol Oncol · 2018-07-17

本研究回顾性分析本机构四年内151例接受根治性放化疗后MRI引导近距离放疗的宫颈癌患者,中位随访26个月,2年局部控制率88.7%、盆腔控制率88.1%、无病生存率82.2%、总生存率94%,晚期3-4级膀胱和肠道毒性发生率为3.8%。作者认为在发展中国家局部晚期广泛宫颈癌患者中,图像引导近距离放疗是改善局部区域控制且远期后遗症有限的有效策略。

要点

  • 患者以FIGO IIB期(53.6%)和IIIB期(23.2%)为主,诊断时肿瘤≥5 cm者占56.3%。
  • 2年局部控制率88.7%、盆腔控制率88.1%、无病生存率82.2%、总生存率94%。
  • 局部失败预测因素为FIGO分期(p=0.002)和诊断时肿瘤大小(p=0.009)。

核心结论

  • 作者认为图像引导近距离放疗是改善局部晚期广泛宫颈癌局部区域控制且远期后遗症有限的有效策略,适用于发展中国家背景。

研究设计与样本

  • 回顾性分析本机构四年内151例接受根治性放化疗后MRI引导近距离放疗的宫颈癌患者,中位随访26个月,采用Kaplan-Meier法估算2年结局。

主要发现

  • 患者以FIGO IIB期(53.6%)和IIIB期(23.2%)为主,诊断时肿瘤≥5 cm者占56.3%,盆腔淋巴结受累者占38.4%。
  • 94%的患者接受了根治性放化疗。
  • 近距离放疗时HRCTV平均体积为42.2 ± 19 cm³,HRCTV平均累积剂量为78.9 ± 5.6 Gy。
  • 2年局部控制率88.7%、盆腔控制率88.1%、无病生存率82.2%、总生存率94%。
  • 局部失败预测因素为FIGO分期(p=0.002)和诊断时肿瘤大小(p=0.009);晚期3-4级膀胱和肠道毒性发生率为3.8%。

临床怎么用

  • 作者认为在发展中国家局部晚期广泛宫颈癌患者中,图像引导近距离放疗是改善局部区域控制且远期后遗症有限的有效策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this series is to study the effectiveness of MRI based image-guided brachytherapy (IGBT) in Indian patients with cervical cancer who mostly present in later stages with bulky diseases. PATIENTS AND METHODS: 151 cervical cancer patients treated at our institution in last four years, with definitive chemoradiation followed by MRI-based brachytherapy were reviewed. With median follow up of 26 months, Kaplan Meier estimates at two years were calculated for local control (LC), pelvic control (PC), disease-free survival (DFS) and overall survival (OS). Also, severe late sequelae were reported. RESULTS: The patients predominantly presented with locally advanced cervical cancer in FIGO stages IIB (53.6%) and IIIB (23.2%). Tumour dimensions at diagnosis were ≥5 cm in 56.3% and pelvic nodal involvement was found in 38.4% of the patients. 94% of the patients received curative chemoradiation. Mean HRCTV volume at the time of brachytherapy was 42.2 ± 19 cm3 and mean cumulative dose to HRCTV was 78.9 ± 5.6 Gy. Overall LC, PC, DFS and OS at 2 years were 88.7%, 88.1%, 82.2% and 94% respectively. The predictors for local failure were FIGO stage (p = 0.002) and tumour size at diagnosis (p = 0.009). Late grade 3-4 bladder and bowel toxicities were observed in 3.8% of the patients. CONCLUSION: Our review demonstrates that IGBT is an effective strategy to improve locoregional control with limited long-term sequelae in patients with locally advanced extensive cervical cancer in the setting of a developing country.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Tiwari R, Narayanan GS, Jayakumar V, et al. The promise of image-guided brachytherapy of better clinical outcomes in treatment of cervical cancer: Does it deliver? An Indian scenario. Gynecol Oncol. 2018. PMID: 30017538. doi:10.1016/j.ygyno.2018.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。